<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="30%"></col>
<col width="16%"></col>
<col width="54%"></col>
<tbody>
<tr>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="bottom">
<paragraph>
<content stylecode="bold">Concomitant Drug Class:</content>
<br/>
<content stylecode="bold">Drug Name</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="bottom">
<paragraph>
<content stylecode="bold">Effect on Concentration</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="bottom">
<paragraph>
<content stylecode="bold">Clinical Comment</content>
</paragraph>
</td>
</tr>
<tr>
<td align="center" colspan="3" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">HIV-1 Antiviral Agents</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
</paragraph>
<paragraph>Etravirine<sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Use of TRIUMEQ with etravirine without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
</paragraph>
<paragraph>Efavirenz<sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Adjust dolutegravir dose to 50 mg twice daily. An additional 50-mg dose of dolutegravir should be taken, separated by 12 hours from TRIUMEQ.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
</paragraph>
<paragraph>Nevirapine</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Avoid coadministration with TRIUMEQ because there are insufficient data to make dosing recommendations.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Protease inhibitor:</content>
</paragraph>
<paragraph>Fosamprenavir/ritonavir<sup>a</sup>
<br/>Tipranavir/ritonavir<sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Adjust dolutegravir dose to 50 mg twice daily. An additional dolutegravir 50-mg dose should be taken, separated by 12 hours from TRIUMEQ.</paragraph>
</td>
</tr>
<tr>
<td align="center" colspan="3" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Other Agents</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Carbamazepine<sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Adjust dolutegravir dose to 50 mg twice daily. An additional dolutegravir 50-mg dose should be taken, separated by 12 hours from TRIUMEQ.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Oxcarbazepine<br/>Phenytoin<br/>Phenobarbital<br/>St. John’s wort (<content stylecode="italics">Hypericum perforatum</content>)</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Avoid coadministration with TRIUMEQ because there are insufficient data to make dosing recommendations.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Medications containing polyvalent cations</content>
<br/>
<content stylecode="bold">(e.g., Mg or Al):</content>
</paragraph>
<paragraph>Cation-containing antacids<sup>a</sup> or laxatives<br/>Sucralfate<br/>Buffered medications</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Administer TRIUMEQ 2 hours before or 6 hours after taking medications containing polyvalent cations.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Oral calcium and iron supplements, including multivitamins containing calcium or iron<sup>a</sup>
</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Administer TRIUMEQ 2 hours before or 6 hours after taking supplements containing calcium or iron. Alternatively, TRIUMEQ and supplements containing calcium or iron can be taken together with food.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Metformin<sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>↑Metformin</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TRIUMEQ. When stopping TRIUMEQ, the metformin dose may require an adjustment. Monitoring of blood glucose when initiating concomitant use and after withdrawal of TRIUMEQ is recommended.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule ">
<paragraph>Rifampin<sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule ">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule ">
<paragraph>Adjust dolutegravir dose to 50 mg twice daily. An additional 50-mg dose of dolutegravir should be taken, separated by 12 hours from TRIUMEQ. </paragraph>
</td>
</tr>
</tbody>
</table>